Sulzer Medica begins trials of new implantable cardioverter-defibrillator (ICD):
This article was originally published in Clinica
A Canadian woman has become the first patient to receive a new implantable cardioverter-defibrillator capable of distinguishing life threatening irregular heart beats from their non fatal counterparts. The Res-Q Micron Advantage, developed by Sulzer Medica, is designed to deliver electric shocks to treat ventricular arrhythmias while preventing unnecessary shocks to patients with non-ventricular arrhythmias.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.